Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Low molecular weight heparin]

M Pini1

  • 1Dipartimento di Medicina, Ospedale, Fidenza, Azienda USL di Parma.

Recenti Progressi in Medicina
|April 2, 1998
PubMed
Summary
This summary is machine-generated.

Low-molecular-weight heparins (LMWHs) offer improved efficacy and safety over standard heparin for preventing and treating blood clots. Their pharmacokinetic advantages and reduced platelet interaction make them increasingly preferred in various clinical settings.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Characterization of diarylethene-based photoswitches with core and valence photoabsorption and photoemission spectroscopies.

The Journal of chemical physics·2026
Same author

Mutual friction and vortex Hall angle in a strongly interacting Fermi superfluid.

Nature communications·2025
Same author

Direct temporal characterization of sub-3-fs deep UV pulses generated by resonant dispersive wave emission: erratum.

Optics express·2025
Same author

Direct temporal characterization of sub-3-fs deep UV pulses generated by resonant dispersive wave emission.

Optics express·2023
Same author

Argentine tango in the care of Parkinson's disease: A systematic review and analysis of the intervention.

Complementary therapies in medicine·2020
Same author

'Real-life' report on the management of chronic GvHD in the Gruppo Italiano Trapianto Midollo Osseo (GITMO).

Bone marrow transplantation·2017
Same journal

Recenti progressi in medicina·2026
Same journal

Recenti progressi in medicina·2026
Same journal

Recenti progressi in medicina·2026
Same journal

Recenti progressi in medicina·2026
Same journal

Recenti progressi in medicina·2026
Same journal

Recenti progressi in medicina·2026
See all related articles

Area of Science:

  • Pharmacology
  • Hematology
  • Internal Medicine

Background:

  • Standard heparin has limitations including variable pharmacokinetics and higher platelet interaction.
  • Low-molecular-weight heparins (LMWHs) are derived from standard heparin through depolymerization.
  • LMWHs offer distinct pharmacokinetic profiles and reduced platelet interaction compared to standard heparin.

Purpose of the Study:

  • To review the clinical advantages and applications of LMWHs.
  • To compare the efficacy and safety of LMWHs with unfractionated heparin and oral anticoagulants.
  • To evaluate the role of LMWHs in various thromboembolic conditions.

Main Methods:

  • Review of clinical studies and data on LMWH use.
  • Comparative analysis of LMWH efficacy and safety against standard heparin and oral anticoagulants.

Related Experiment Videos

  • Examination of LMWH applications in venous thromboembolism prophylaxis and treatment, acute coronary syndromes, and ischemic stroke.

    • Main Results:

    • LMWHs are more efficacious than unfractionated heparin for high-risk venous thromboembolism prophylaxis and equally efficacious for moderate-risk patients, with once-daily dosing.
    • Subcutaneous LMWH treatment for acute deep venous thrombosis and pulmonary embolism shows equivalent efficacy and safety to intravenous unfractionated heparin, enabling home treatment.
    • LMWHs are safer and equally effective as oral anticoagulants for post-acute deep venous thrombosis treatment.
    • Specific LMWHs (nadroparine, enoxaparin) plus aspirin are more effective than unfractionated heparin plus aspirin for unstable angina and non-Q wave myocardial infarction.
    • Preliminary data suggest promise for LMWHs in acute ischemic stroke, pending further studies.

    Conclusions:

    • LMWHs are supplanting standard heparin due to superior pharmacokinetic properties and reduced side effects.
    • LMWHs demonstrate significant benefits in efficacy, safety, and administration convenience across a spectrum of thromboembolic disorders.
    • Further research is ongoing to fully establish the role of LMWHs in conditions like acute ischemic stroke.